Lymphoma

The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.

The use of a fixed-duration regimen of glofitamab several days after pretreatment with obinutuzumab was associated with high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

The FDA’s acceptance of the biologics license application for denileukin diftitox for the treatment of patients with cutaneous persistent or recurrent T-cell lymphoma was supported by data from a pivotal phase 3 trial.

The allogeneic anti-CD19 CAR-T cell therapy CB-010 has received 2 designations from the FDA, including a fast-track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

Real-world data show effective outcomes following ibrutinib and rituximab treatment in patients with relapsed/refractory mantle cell lymphoma with bone marrow involvement.

Patients with relapsed/refractory large B-cell lymphoma may benefit from epcoritamab, which received priority review from the FDA.

Topline results from the phase 2 MIRAGE study indicated that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma receiving zandelisib experienced an objective response rate of 75.4%.

Andre H. Goy, MD, discussed the most pressing unresolved questions in the current treatment of MCL in an interview with the journal ONCOLOGY.

For camidanlumab tesirine to be considered for an accelerated approval path in relapsed/refractory Hodgkin lymphoma, the FDA has strongly recommended conducting confirmatory phase 3 research at the time of biologic license application submission.

Patients with previously untreated high-risk pediatric lymphoma can now receive treatment with brentuximab vedotin with the FDA’s nod of approval.

Findings from a randomized phase 3 trial indicated that brentuximab vedotin plus chemotherapy yielded a higher event-free survival rate and lowered the risk of death compared with chemotherapy alone among patients with advanced-stage Hodgkin Lymphoma.

Real-world results from the retrospective SCHOLAR-2 study provided a benchmark for survival in patients with relapsed or recurrent refractory mantle cell lymphoma who received salvage therapy following failure of initial Bruton tyrosine kinase inhibitor therapy.

Atezolizumab plus R-CHOP appeared to yield durable clinical benefit and a safety profile consistent with known toxicities in patients with previously untreated DLBCL, according to data from a phase 1b/2 trial.

Patients with relapsed/refractory large B-cell lymphoma may benefit from epcoritamab, the biologics license applications of which were submitted to the FDA.

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA.

The European Commission based its approval of axicabtagene ciloleucel as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma on the efficacy findings of the phase 3 ZUMA-7 trial.

Tycel Phillips, MD, reviewed effective second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, spoke about key data from the phase 3 SHINE trial which analyzed the use of first-line ibrutinib plus bendamustine and rituximab in older patients with mantle cell lymphoma.

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

Patients with mantle cell lymphoma experienced higher relative risks of respiratory, blood, and infectious disease relative to the general population, regardless of treatment type.

Tafasitamab plus lenalidomide prolonged overall survival compared with systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma, according to data from the retrospective RE-MIND2 study.

Closing out their review of tazemetostat in R/R FL, participants consider its practical use in practice alongside other novel treatment modalities.

Data from a pivotal phase 3 trial support a recent biologics license application for denileukin diftitox that was submitted to the FDA.

Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.

In an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.

Experts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.

Drs Goy, Ip, and Leslie close out their discussion with a look at the exciting developments and future of CAR T-cell therapies in lymphoma treatment.

Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.

Opening their discussion on relapsed/refractory follicular lymphoma (R/R FL), expert participants review the spectrum of available treatments in this setting.

In an interview, Kami J. Maddocks, MD, showed her excitement about future use of bispecific antibodies for the treatment of lymphomas.